Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Dupage Medical Group
585
mi
from
Winfield, IL
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Dupage Medical Group
585
mi
from
Winfield, IL
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Urology of Indiana LLC
630
mi
from
Avon, IN
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Urology of Indiana LLC
630
mi
from
Avon, IN
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Metropolitan Urology P.S.C
627
mi
from
Jefferson, IN
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Metropolitan Urology P.S.C
627
mi
from
Jefferson, IN
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Kansas City Urology Care, PA
190
mi
from
Overland Park, KA
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Kansas City Urology Care, PA
190
mi
from
Overland Park, KA
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology Research Associates
1148
mi
from
Glen Burnie, MD
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology Research Associates
1148
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology Research Associates
1147
mi
from
Towson, MD
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology Research Associates
1147
mi
from
Towson, MD
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Men's Health Boston
1438
mi
from
Chestnut Hill, MA
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Men's Health Boston
1438
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Center for Male Reproductive Medicine
1285
mi
from
Hackensack, NJ
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Center for Male Reproductive Medicine
1285
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Premier Urology Assoc LLC dba AdvanceMed Research
1247
mi
from
Lawrenceville, NJ
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Premier Urology Assoc LLC dba AdvanceMed Research
1247
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Community Care Physicians
1307
mi
from
Albany, NY
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Community Care Physicians
1307
mi
from
Albany, NY
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Bruce R. GIlbert, MD, PhD, PC
1301
mi
from
Great Neck, NY
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Bruce R. GIlbert, MD, PhD, PC
1301
mi
from
Great Neck, NY
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Manhattan Medical Research Practice PLLC
1288
mi
from
New York, NY
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Manhattan Medical Research Practice PLLC
1288
mi
from
New York, NY
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Michael A. Werner, MD PC
1302
mi
from
Purchase, NY
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Michael A. Werner, MD PC
1302
mi
from
Purchase, NY
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Associated Urologists of North Carolina
1068
mi
from
Raleigh, NC
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Associated Urologists of North Carolina
1068
mi
from
Raleigh, NC
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Tristate Urologic Services dba TUG Research
729
mi
from
Cincinnati, OH
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Tristate Urologic Services dba TUG Research
729
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Urology Clinics of North Texas
342
mi
from
Dallas, TX
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Urology Clinics of North Texas
342
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Jean Brown Research
777
mi
from
Salt Lake City, UT
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Jean Brown Research
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Virginia Urology
1113
mi
from
Richmond, VA
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Virginia Urology
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Urology of Virginia, PLLC
1196
mi
from
Virginia Beach, VA
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Urology of Virginia, PLLC
1196
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated:  12/31/1969
Urologic Consultants of SE PA
1225
mi
from
Bala-Cynwyd, PA
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Status: Enrolling
Updated: 12/31/1969
Urologic Consultants of SE PA
1225
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk
Intestinal Microbiota and Short Term Outcomes in Very Low Birth Weight Infants Fed Primarily Donor Human Milk Compared to Infants Fed Primarily Mother's Own Milk
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Texas Children's Hospital
569
mi
from
Houston, TX
Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk
Intestinal Microbiota and Short Term Outcomes in Very Low Birth Weight Infants Fed Primarily Donor Human Milk Compared to Infants Fed Primarily Mother's Own Milk
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Texas Children's Hospital
569
mi
from
Houston, TX
Click here to add this to my saved trials
Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk
Intestinal Microbiota and Short Term Outcomes in Very Low Birth Weight Infants Fed Primarily Donor Human Milk Compared to Infants Fed Primarily Mother's Own Milk
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
572
mi
from
Houston, TX
Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk
Intestinal Microbiota and Short Term Outcomes in Very Low Birth Weight Infants Fed Primarily Donor Human Milk Compared to Infants Fed Primarily Mother's Own Milk
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
572
mi
from
Houston, TX
Click here to add this to my saved trials
Cervical Cancer Screening Intervention Among Korean American Women
Facilitating Cervical Cancer Screening Among Underserved Korean American Women
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
1229
mi
from
Philadelphia, PA
Cervical Cancer Screening Intervention Among Korean American Women
Facilitating Cervical Cancer Screening Among Underserved Korean American Women
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
1229
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Fetal Body Composition and Volumes Study
Fetal Body Composition and Volumes Study
Status: Enrolling
Updated:  12/31/1969
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
1123
mi
from
Bethesda, MD
Fetal Body Composition and Volumes Study
Fetal Body Composition and Volumes Study
Status: Enrolling
Updated: 12/31/1969
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated:  12/31/1969
Creighton University
262
mi
from
Omaha, NE
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated: 12/31/1969
Creighton University
262
mi
from
Omaha, NE
Click here to add this to my saved trials
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
1286
mi
from
New York, NY
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
Early Versus Late Voiding Trials After Prolapse Repair
Normal Voiding Function After Surgical Repair of Pelvic Organ Prolapse: A Randomized Trial Comparing Day of Surgery Retrograde Void Trials to Standard Postoperative Day One Retrograde Void Trials
Status: Enrolling
Updated:  12/31/1969
Magee-Womens Hospital of UPMC
974
mi
from
Pittsburgh, PA
Early Versus Late Voiding Trials After Prolapse Repair
Normal Voiding Function After Surgical Repair of Pelvic Organ Prolapse: A Randomized Trial Comparing Day of Surgery Retrograde Void Trials to Standard Postoperative Day One Retrograde Void Trials
Status: Enrolling
Updated: 12/31/1969
Magee-Womens Hospital of UPMC
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
1258
mi
from
Basking Ridge, NJ
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
1258
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center at Commack
1324
mi
from
Commack, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center at Commack
1324
mi
from
Commack, NY
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Rockville Centre
1305
mi
from
Rockville Centre, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
1305
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
1280
mi
from
Middletown, NJ
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
1280
mi
from
Middletown, NJ
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
1301
mi
from
Harrison, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
1301
mi
from
Harrison, NY
Click here to add this to my saved trials
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northwest
1398
mi
from
Hillsboro, OR
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northwest
1398
mi
from
Hillsboro, OR
Click here to add this to my saved trials
A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study
A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study
A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Shared Decision Making for Prescription Opioids After Cesarean Delivery
Shared Decision Making for Prescription Opioids After Cesarean Delivery
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Shared Decision Making for Prescription Opioids After Cesarean Delivery
Shared Decision Making for Prescription Opioids After Cesarean Delivery
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Comparing Different Methods of Patient Education on Preeclampsia
Comparing Different Methods of Patient Education on Preeclampsia: A Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Geisinger Maternal Fetal Medicine
1191
mi
from
Forty Fort, PA
Comparing Different Methods of Patient Education on Preeclampsia
Comparing Different Methods of Patient Education on Preeclampsia: A Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Geisinger Maternal Fetal Medicine
1191
mi
from
Forty Fort, PA
Click here to add this to my saved trials
Comparing Different Methods of Patient Education on Preeclampsia
Comparing Different Methods of Patient Education on Preeclampsia: A Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center: Maternal Fetal Medicine and Prenatal Clinics
1151
mi
from
Danville, PA
Comparing Different Methods of Patient Education on Preeclampsia
Comparing Different Methods of Patient Education on Preeclampsia: A Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center: Maternal Fetal Medicine and Prenatal Clinics
1151
mi
from
Danville, PA
Click here to add this to my saved trials
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente
1165
mi
from
Downey, CA
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente
1165
mi
from
Downey, CA
Click here to add this to my saved trials
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente
1136
mi
from
San Diego, CA
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente
1136
mi
from
San Diego, CA
Click here to add this to my saved trials
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated:  12/31/1969
University of California at San Diego Antiviral Research Center
1142
mi
from
San Diego, CA
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated: 12/31/1969
University of California at San Diego Antiviral Research Center
1142
mi
from
San Diego, CA
Click here to add this to my saved trials
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated:  12/31/1969
San Francisco General Hospital - Infectious Diseases
1339
mi
from
San Francisco, CA
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated: 12/31/1969
San Francisco General Hospital - Infectious Diseases
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated:  12/31/1969
Cook County Health and Hospitals System - Ruth M Rothstein CORE Center
609
mi
from
Chicago, IL
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated: 12/31/1969
Cook County Health and Hospitals System - Ruth M Rothstein CORE Center
609
mi
from
Chicago, IL
Click here to add this to my saved trials
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit
414
mi
from
Saint Louis, MO
LACTIN-V Study for Recurrent Bacterial Vaginosis
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Neuropathic Pain in Pregnancy
Neuropathic Pain in Pregnancy
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Neuropathic Pain in Pregnancy
Neuropathic Pain in Pregnancy
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Click here to add this to my saved trials
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
Status: Enrolling
Updated:  12/31/1969
Yale University
1344
mi
from
New Haven, CT
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
Status: Enrolling
Updated: 12/31/1969
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
Status: Enrolling
Updated:  12/31/1969
University Health Network-Princess Margaret Hospital
1045
mi
from
Toronto,
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
Status: Enrolling
Updated: 12/31/1969
University Health Network-Princess Margaret Hospital
1045
mi
from
Toronto,
Click here to add this to my saved trials
Uterosacral Ligament Suspension vs Robotic Sacrocolpopexy
Long Term Outcomes of Uterosacral Ligament Suspension Versus Robotic Sacrocolpopexy
Status: Enrolling
Updated:  12/31/1969
Cincinnati Urogynecology Associates
725
mi
from
Cincinnati, OH
Uterosacral Ligament Suspension vs Robotic Sacrocolpopexy
Long Term Outcomes of Uterosacral Ligament Suspension Versus Robotic Sacrocolpopexy
Status: Enrolling
Updated: 12/31/1969
Cincinnati Urogynecology Associates
725
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair
Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair: a Prospective Randomised Pilot Study
Status: Enrolling
Updated:  12/31/1969
University of California San Francisco - Center for Reproductive Health
1337
mi
from
San Francisco, CA
Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair
Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair: a Prospective Randomised Pilot Study
Status: Enrolling
Updated: 12/31/1969
University of California San Francisco - Center for Reproductive Health
1337
mi
from
San Francisco, CA
Click here to add this to my saved trials
Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes
Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes
Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials